AEGERA INITIATES CLINICAL TRIAL FOR AEG35156
Aegera Therapeutics has announced the initiation of its third human clinical study for AEG35156, the company's proprietary therapeutic targeting the X-linked Inhibitor of Apoptosis Protein (XIAP), a key regulator of apoptosis. This Phase I trial is an open-label study of AEG35156 administered in combination with ara-C and idarubicin in patients with refractory or relapsed acute myeloid leukemia (AML).
The trial is being conducted at two leading North American cancer centers: the University of Texas M. D. Anderson Cancer Center in Houston, Texas; and Princess Margaret Hospital, part of University Health Network in Toronto, Ontario. It is designed to find an effective and safe dose to treat leukemia patients.